Ask AI
ProCE Banner Activity

Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

Podcast Episodes

In this episode, 2 experts discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including the clinical impact of first-generation therapies and challenges related to resistance. They also explore emerging next-generation inhibitors and combination strategies that may expand treatment options and improve patient outcomes.

Released: March 10, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Lilly.

Genentech, a member of the Roche Group

Lilly

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with NSCLC who may be eligible for treatment with next-generation KRAS G12C–targeted therapies when they become available

  • Consider how next-generation KRAS G12C–targeted agents in late-phase clinical trials might be integrated into real-world clinical practice for patients with NSCLC

  • Discuss with colleagues and patients ongoing advances in targeting KRAS G12C for solid tumors

Disclosure

Primary Author

Christine Bestvina, MD: advisor: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi, EMD Serono, Genentech, Gilead, Guardant, Jazz, Johnson & Johnson, Lilly, Mirati, Novartis, Pfizer, Summit, Tempus, Turning Point Therapeutics, Voroni; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb.

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Lilly, Merck KGaA, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi; researcher: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer; other financial or material support: AstraZeneca, Janssen, Merck, Mirati, Sanofi.